AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...

Zac Veen has lost a bit of his luster as of late, but one of the brightest young stars in the Colorado Rockies' farm system could very well turn things around this season. MLB.com's Ben Weinrib ...

Among patients with KRAS G12C mutations, candidate primary resistance mutations were detected in many patients with colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC), which may ...

No. 3 prospect Zac Veen, trying to earn a roster spot after two injury-plagued seasons, started in left field and hit a two-run homer in the fourth. Veen also stole second base in the second.